FDA Inspection 1100058 — Kite Pharma, Inc.

Kite Pharma, Inc. — FEI 3012583739

The FDA completed an inspection of Kite Pharma, Inc. on August 20, 2019 in El Segundo, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 3 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 20, 2019
Fiscal Year
2019
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
El Segundo, CA (United States)

Citations

IDCFRDescription
135821 CFR 211.100(b)SOPs not followed / documented
189021 CFR 211.165(e)Test methods
908921 CFR 600.14(c)When to report